ISRG vs LMAT vs MCK Stock Comparison

Intuitive Surgical, Lemaitre Vascular and Mckesson Prices as of Oct 27, 2026 Peers: Industry group
ISRG Intuitive Surgical Inc
$445.88 +10.0% 1M -19.1% 1Y
Market cap
$155.46B
P/E
52.6x
Revenue (TTM)
$11.58B
Div. yield
–
Medical Devices Healthcare
3 wins
LMAT Lemaitre Vascular Inc
$83.79 +2.8% 1M -7.0% 1Y
Market cap
$1.90B
P/E
29.0x
Revenue (TTM)
$262.43M
Div. yield
0.01%
Medical Devices Healthcare
2 wins
MCK Mckesson Corp
$967.03 +11.6% 1M +19.2% 1Y
Market cap
$113.87B
P/E
24.8x
Revenue (TTM)
$410.98B
Div. yield
0.00%
Drug Distribution Healthcare
5 wins

Head to Head

10 decided of 12

Mckesson leads on 5 of the 12 questions below (Mckesson 5, Intuitive Surgical 3, Lemaitre Vascular 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionISRGLMATMCKLeader
Larger companyMarket capitalisation $155.46B $1.90B $113.87B ISRG
Cheaper on earningsLower P/E, profitable companies only 52.6x 29.0x 24.8x MCK
Cheaper on forward earningsLower price / next fiscal year consensus EPS 38.9x 28.4x 20.5x MCK
Faster revenue growthRevenue growth, trailing twelve months +20.5% +11.8% +8.8% ISRG
More profitableNet margin, trailing twelve months 25.5% 25.0% 1.1% ISRG
Better return on capitalReturn on invested capital — — 107.9% –
Less leveragedLower net debt / EBITDA — — 0.6x –
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% LMAT
Better 1-year returnPrice return, last 12 months -19.1% -7.0% +19.2% MCK
Better 5-year returnAnnualised price return, 5 years +4.6%/yr +8.3%/yr +36.4%/yr MCK
Less volatileAnnualised volatility, 1 year 34.6% 46.1% 30.7% MCK
Higher overall scoreMean of the five percentile scores vs peers 80/100 83/100 57/100 LMAT

Percentile Scorecard

ISRGLMATMCK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisISRGLMATMCK
Valuation 54 #106 of 227 74 #59 of 227 50 #13 of 25
Growth 80 #45 of 219 89 #25 of 219 65 #9 of 24
Profitability 98 #6 of 206 96 #9 of 206 61 #10 of 24
Financial Health 78 #53 of 238 90 #25 of 238 52 #13 of 26
Shareholder Returns 92 #12 of 134 64 #49 of 134 57 #7 of 15
Overall 80 83 57
  • ISRG ranked among 247 companies in Medical Devices and Diagnostics
  • LMAT ranked among 247 companies in Medical Devices and Diagnostics
  • MCK ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodISRGLMATMCKSPY
1 month +10.0%+2.8%+11.6% -0.2%
3 months +23.2%-18.1%+8.7% +3.9%
6 months -4.4%-25.5%+15.8% +8.2%
Year to date -21.3%+3.3%+17.9% +12.9%
1 year -19.1%-7.0%+19.2% +12.3%
3 years +72.2%+76.8%+115.8% +87.4%
3 years, per year +19.9%+20.9%+29.3% +23.3%
5 years +25.4%+49.0%+371.7% +67.9%
5 years, per year +4.6%+8.3%+36.4% +10.9%
10 years +505.1%+296.9%+502.5% +261.1%
10 years, per year +19.7%+14.8%+19.7% +13.7%

Risk

MeasureISRGLMATMCKSPY
Volatility, 1Y 34.6%46.1%30.7% 12.7%
Downside volatility, 1Y 37.4%52.9%27.4% 12.7%
Beta vs S&P 500, 1Y 0.890.43-0.27 1.00
Return / volatility, 1Y -0.55-0.150.62 0.97
Max drawdown, 5Y -49.9%-33.5%-27.2% -25.4%
From 52-week high -24.8%-28.6%-6.1% -1.2%
52-week high $592.85$117.39$1,030.18 $779.14
52-week low $332.02$78.80$725.17 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleISRGLMATMCK
P/E now vs peer median 52.6xmedian 29.6x 29.2xmedian 29.6x 25.0xmedian 23.9x
P/S now vs peer median 13.3xmedian 2.9x 7.3xmedian 2.9x 0.3xmedian 0.3x
EV/EBITDA now vs peer median 36.8xmedian 17.4x 17.4xmedian 17.4x 16.2xmedian 13.4x
P/FCF now vs peer median 43.0xmedian 22.3x 26.0xmedian 22.3x 17.6xmedian 15.5x
P/B now vs peer median 9.6xmedian 2.3x 4.6xmedian 2.3x -26.6xmedian 2.5x
PEG now vs peer median 2.05median 1.04 0.87median 1.04 2.09median 1.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsISRGLMATMCK
Revenue $11.58B $262.43M $410.98B
Gross profit $7.78B $191.31M $14.96B
Operating income $3.28B $77.32M $6.50B
Net income $2.97B $65.67M $5.30B
Free cash flow $3.60B $73.83M $6.42B
R&D $1.49B $15.41M –
EPS (diluted) $8.41 $2.68 $38.52
Cash & equivalents $2.98B $26.63M $5.16B
Total debt – – $9.73B
Shares (diluted) 351.60M 24.53M 119.20M
Enterprise value $135.74B $458.65M $97.77B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricISRGLMATMCK
P/E 52.6x 29.2x 25.0x
P/FCF 43.0x 26.0x 17.6x
P/Operating cash flow 37.8x 23.1x 16.5x
P/S 13.3x 7.3x 0.3x
P/B 9.6x 4.6x -26.6x
P/Tangible book 10.4x 4.9x -13.7x
EV/EBITDA 36.8x 17.4x 16.2x
EV/EBIT 45.8x 19.9x 18.1x
EV/Revenue 13.0x 5.9x 0.3x
EV/FCF 41.8x 20.9x 18.3x
EV/Operating cash flow 36.8x 18.6x 17.1x
PEG (3Y EPS CAGR) 2.05 0.87 2.09

Growth

14 metrics
MetricISRGLMATMCK
Revenue growth (1Y) 20.5% 11.8% 8.8%
Revenue CAGR (3Y) 19.1% 14.0% 13.1%
Gross profit growth (1Y) 21.9% 18.0% 11.2%
Gross profit CAGR (3Y) 19.5% 18.8% 6.6%
Operating income growth (1Y) 16.6% 41.2% 46.6%
Operating income CAGR (3Y) 24.8% 36.4% 13.5%
Net income growth (1Y) 7.5% 39.4% 58.1%
Net income CAGR (3Y) 24.4% 37.6% 10.7%
EPS growth (1Y) 10.8% 30.1% 52.8%
EPS CAGR (3Y) 25.7% 33.6% 12.0%
Operating cash flow growth (1Y) 38.1% 41.2% 4.7%
Operating cash flow CAGR (3Y) 26.4% 48.0% 10.7%
Free cash flow growth (1Y) 58.4% 41.1% 6.8%
Free cash flow CAGR (3Y) 42.0% 57.4% 11.3%

Profitability

14 metrics
MetricISRGLMATMCK
Gross margin 67.2% 72.9% 3.6%
EBITDA margin 35.3% 33.8% 1.8%
Operating margin 28.4% 29.5% 1.6%
Pretax margin 31.3% 32.3% 1.6%
Net margin 25.5% 25.0% 1.1%
FCF margin 31.1% 28.1% 1.6%
Operating cash flow margin 35.3% 31.6% 1.7%
Return on equity 17.3% 15.9% –
Return on assets 14.8% 10.3% 6.2%
Return on invested capital – – 107.9%
Return on capital employed 18.7% 12.8% 43.4%
Asset turnover 0.6x 0.4x 4.8x
Cash conversion (OCF / net income) 1.4x 1.3x 1.3x
Stock comp / revenue 7.2% 3.0% –

Financial Health

11 metrics
MetricISRGLMATMCK
Debt / assets – – 11.0%
Debt / equity – – -2.3x
Net debt / EBITDA – – 0.6x
Debt / FCF – – 1.5x
Liabilities / assets 16.7% 34.4% 104.8%
Equity / assets 83.3% 65.6% -4.8%
Interest coverage – 14.9x 23.6x
Current ratio 3.3x 16.3x 0.9x
Quick ratio 2.3x 13.8x 0.5x
Cash ratio 1.6x 12.6x 0.1x
Altman Z-score 30.55 7.34 5.89

Shareholder Returns

7 metrics
MetricISRGLMATMCK
Dividend yield – 1.1% 0.4%
Net buyback yield 2.8% -0.3% 5.9%
Shareholder yield 2.8% 0.8% 6.2%
Payout ratio (earnings) – 31.2% 7.4%
Payout ratio (FCF) – 27.8% 6.1%
Dividend growth (1Y) – 26.3% 11.3%
Dividend CAGR (3Y) – 20.5% 10.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusISRGLMATMCK
Forward P/E 38.9xFY2026 28.4xFY2026 20.5xFY2026
EPS, next fiscal year $11.47FY2026 $2.95FY2026 $47.15FY2026
EPS growth, next FY +28.4%FY2026 +17.1%FY2026 +20.6%FY2026
EPS growth, the year after +4.5% +12.9% +11.0%
Revenue, next fiscal year $11.60BFY2026 $266.90MFY2026 $444.47BFY2026
Revenue growth, next FY +15.3%FY2026 +6.9%FY2026 +10.2%FY2026
Revenue growth, the year after +11.3% +19.4% +1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersISRGLMATMCK
Held by institutions 86.2% 99.3% 89.1%
Institutions holding 2,235 327 2,009
Change in shares held, QoQ +4.6% +2.8% -0.7%
Institutions buying 1,070 172 881
Institutions selling 877 98 791
Buyers to sellers 1.22 1.76 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ISRGLMATMCK
ISRG 1.00 0.23 0.11
LMAT 0.23 1.00 -0.01
MCK 0.11 -0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ISRG, LMAT and MCK?

Intuitive Surgical (ISRG) is the largest by market capitalisation: Intuitive Surgical (ISRG) $155.46B, Lemaitre Vascular (LMAT) $1.90B, Mckesson (MCK) $113.87B.

Which stock is cheaper, ISRG, LMAT and MCK?

Mckesson (MCK) trades on the lowest price-to-earnings ratio (Intuitive Surgical (ISRG) 52.6x, Lemaitre Vascular (LMAT) 29.0x, Mckesson (MCK) 24.8x). On next year's consensus earnings, Mckesson (MCK) is cheapest (Intuitive Surgical (ISRG) 38.9x, Lemaitre Vascular (LMAT) 28.4x, Mckesson (MCK) 20.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Intuitive Surgical (ISRG) grew revenue fastest over the trailing twelve months: Intuitive Surgical (ISRG) +20.5%, Lemaitre Vascular (LMAT) +11.8%, Mckesson (MCK) +8.8%.

Which company is more profitable?

Intuitive Surgical (ISRG) has the highest net margin (Intuitive Surgical (ISRG) 25.5%, Lemaitre Vascular (LMAT) 25.0%, Mckesson (MCK) 1.1%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: Intuitive Surgical (ISRG) -19.1%, Lemaitre Vascular (LMAT) -7.0%, Mckesson (MCK) +19.2%. Over five years, Mckesson (MCK) compounded fastest (Intuitive Surgical (ISRG) +4.6%/yr, Lemaitre Vascular (LMAT) +8.3%/yr, Mckesson (MCK) +36.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Lemaitre Vascular (LMAT) has the highest dividend yield: Intuitive Surgical (ISRG) 0.00%, Lemaitre Vascular (LMAT) 0.01%, Mckesson (MCK) 0.00%. Intuitive Surgical (ISRG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Intuitive Surgical (ISRG) 34.6%, Lemaitre Vascular (LMAT) 46.1%, Mckesson (MCK) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ISRG, LMAT and MCK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.